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SLEEPING PATENTS AND COMPULSORY LICENSING:
AN OPTIONS ANALYSIS
1 Introduction
Is it ever rational for a potentially profitable invention to be left unexploited?  And why
should a firm ever wish to create a patent that it does not use?  In law, economics and
popular mythology it is generally presumed that any situation in which a firm wishes to
hold a sleeping patent is detrimental to society as a whole.  In the Xerox case, for
example, the company was alleged to have taken out patents over inferior technologies
in order to block entry and protect its dominant position.  Another possibility, perhaps
more significant in popular perception than in reality, is an invention that is ‘too
drastic’, threatening to wipe out an entire industry with its improved efficiency.1  In
consequence of this view, UK patent law (and similar provisions in a number of other
countries) provides for compulsory licensing of a new technology in cases where the
patent-holder itself refuses to exploit it, despite market potential.2
This issue is the concern of on-going policy debate.  In a recent issue of the
Antitrust Law Journal, a symposium of articles considers possible legal remedies to
address the problem of sleeping patents, essentially taking it for granted that the refusal
to license an unused patent is an abusive and anticompetitive practice (see, inter alia,
Crew (1998), Cohen and Burke (1998) and Chin (1998)).  In the United States neither
intellectual property law nor the antitrust laws permit any measures to be taken against
non-exploitation of a patent.  Following a number of unsuccessful antitrust cases
relating to this issue there is some pressure to introduce compulsory licensing
provisions into US law.
In this paper we analyze a two-stage investment project, with research undertaken
in the first stage and irreversible market entry in the second, and consider
circumstances under which the project will be suspended at the intermediate point
between the two stages.  We show that, in the presence of economic and technological
uncertainty, optimizing behavior may result in a firm suspending the project at the
intermediate point, leaving a potentially profitable technology unexploited for some
period of time.  This outcome arises in the absence of rivalry, either for the patent or in
2the product market, removing the anticompetitive motive for sleeping patents.
Although it would be incorrect to conclude from this analysis that a sleeping patent is
never held for anticompetitive purposes, the fact that sleeping patents may arise in
other circumstances means that the observation of an unused yet marketable
technology cannot, in itself, be taken as proof of anticompetitive behavior.  This
conclusion should be borne in mind when considering any proposed reform of the legal
treatment of sleeping patents.
We demonstrate that, if economic uncertainty is high or the expected rate of
innovation is low, it may be rational for a firm to carry out research at times when
market profitability is below the level that would induce exploitation of the new
technology.  Thus research is carried out prospectively with a strong possibility that,
once obtained, the patent will be left dormant for some time.  The intuition for this
result lies in a trade-off between two potential costs facing the firm.  By carrying out
research while conditions are not sufficiently favorable to induce market entry, the firm
incurs the costs of research to gain an investment option that may not be exercised for
an extended period of time.  During this period it bears an opportunity cost given by
the risk-free return on this investment.  If, on the other hand, the firm delays research
until conditions improve, it is likely that the discovery will not be achieved until some
time after market entry would have been desirable.  During this period the firm forgoes
the product market profits which it would have earned had it been in a position to
enter the market immediately.
The ability to suspend the project after the research phase, holding an exclusive
patent over the newly-acquired technology, is crucial to the decision to carry out
prospective research.  We consider the effects of policy measures to enforce the
immediate exploitation of a patent, such as compulsory licensing, and analyze their
impact on the firm’s incentives to engage in research.  We find that restrictions on the
firm’s ability to suspend the project by holding a sleeping patent are likely to suppress
research activity itself, an outcome that is particularly harmful in the presence of
positive spillovers from R&D.
A number of papers analyze two-stage investment projects with possible
suspension.  Dixit and Pindyck (1994; pages 327-328) consider a general two-stage
investment project with uncertain returns, where the first stage may be interpreted as
research.  When investment takes no time to complete, the firm waits until market
3entry is optimal and then sinks both the first- and second-stage investments at the same
time.  Thus, research will never be undertaken without the entire project being
completed and sleeping patents will never arise.  In their discussion Dixit and Pindyck
note that if the first stage investment takes time to complete, then suspension at the
intermediate stage is possible.  If the market price were to fall while the first stage is
being completed and reaches a level below the trigger point for the second stage
investment, the project would then be shelved until conditions improve.
A number of models explain initial investment in the early stages of a multi-stage
project through learning-by-doing.  When research activity itself contributes to the
resolution of uncertainty over, for example, total investment costs or final productivity,
exploratory research may be carried out even when the expected NPV of the project is
negative; see, for example, Roberts and Weitzman (1981).  Pindyck (1993) analyzes a
model in which the technical difficulty (in terms of time, materials and effort) of
completing the project is uncertain and this information is revealed only as the
investment is undertaken.  In this case investment has a shadow value above its
contribution to completion of the project, lowering the trigger point at which the
project will be commenced.
In a model closely related to our own, Bar-Ilan and Strange (1998) analyze a two-
stage investment model with time-to-build.  Using numerical solution techniques they
find that if the first stage investment lag is sufficiently long and output price
uncertainty is high, the first-stage trigger may fall below the second-stage trigger and
exploratory investment takes place.  Although the models and their results are similar,
uncertainty over the timing of discovery, rather than a fixed time to completion, is
arguably better suited to the context of research activity where the timing of any
breakthrough is highly unpredictable.  Furthermore, this formulation allows closed-
form solutions to be derived, avoiding the need to rely on numerical results.
The paper is organized as follows.  Section 2 describes the structure of the model
and the sources of uncertainty faced by the firm.  Optimal trigger points for the second
(capital investment) and first (research) stages respectively are derived in sections 3
and 4.  In section 5 it is proven that, under certain conditions, the second stage trigger
point exceeds the first stage trigger and sleeping patents are possible.  Section 6
considers the effects of measures to enforce the exploitation of a sleeping patent.
Section 7 concludes.
42 The model
A single, risk-neutral firm faces the following sequence of investment opportunities.
First, it may carry out a research project which, if successful, leads to the creation of a
new product design.  When discovery takes place the design is patented immediately
so that protection is gained from any subsequent rival discoveries.  Second, the firm
may choose when to invest in productive capacity and enter the product market, with
costless suspension at this stage.  The second stage investment is completely
irreversible.  The sequence of the firm’s investment decisions is illustrated in figure 1.
The firm faces both technological and economic uncertainty.  While the firm invests
in research, discovery is a Poisson arrival.  The economic value of the patent obtained
by the successful inventor is also uncertain, with the price in the relevant product
market following a stochastic process.  The two-stage problem facing the firm can be
analyzed as a compound option: the payoff from exercising the option to engage in
research is the option to make a second investment which, if exercised, will generate a
direct monetary return.
The underlying state variable in the model is the product market price P,3 which
follows a geometric Brownian motion process described by
dP = µPdt + σPdz (1)
where µ is the drift parameter, measuring the expected growth rate of P;
σ > 0 is the instantaneous standard deviation or volatility parameter; and
dz is the increment of a standard Wiener process; dz ∼ N(0, dt).
The drift parameter, µ, must be strictly less than the risk-free interest rate, r, or
otherwise the option to invest will never be exercised.  For ease of exposition it is
assumed that µ = 0; since our focus is on the effects of uncertainty (i.e. the volatility
parameter, σ) rather than the expected growth rate this restriction is unimportant.
In the first stage the firm invests by establishing and operating a research unit.
When the firm engages in research activity, it makes the discovery according to a
Poisson distribution with parameter (or hazard rate) h > 0.  Thus the conditional
probability that the firm makes the breakthrough in a short time interval of length dt
5given that it has not done so before this time is hdt and the density function for the
duration of research is given by the exponential distribution hthe− .  With a constant
hazard rate the research technology is memoryless; there is no stock of accumulated
knowledge that is lost if research activity is ceased.
At any time before discovery occurs investment in research is fully reversible, with
no sunk (or fixed) costs.  A flow cost of C > 0 per unit time is incurred during any
period of research activity, but this ceases as soon as the project is abandoned.  There
is no actual or potential rivalry in the relevant research area, thus the firm is able to
determine the timing of its research activity free from strategic considerations.  The
trigger point at which the first stage investment is undertaken is denoted P1.4  Since the
research process is frictionless, with a memoryless research technology and no sunk
costs, research is both commenced (as P rises) and subsequently abandoned (as P falls)
at this point.5
For ease of exposition the research program can be thought of as h independent
lines of research, each with a hazard rate of unity and an individual flow cost of c.6
Thus the cost parameter can be rewritten as C = ch.  This formulation allows the cost
and hazard rate parameters to be changed in numerical simulations without affecting
the expected value of the project, which would otherwise obscure the option value
effects.
When discovery takes place the firm obtains a patent of infinite duration giving it
exclusive rights over its new design and blocking all rival products.  Patenting is
assumed to be costless and thus will never be delayed; a patent is taken out as soon as
the breakthrough occurs.  For simplicity patent length is assumed to be infinite; this
assumption is irrelevant to the results and the model could be modified to incorporate a
finite patent length.
In order to manufacture and market the new product, physical capital must be
sunk.  This investment, along with market entry itself, is assumed to be totally
irreversible.  The initial investment cost is denoted I and production incurs a flow cost,
w.  Demand is completely inelastic at one unit, thus flow profits per unit time are given
by (P–w).  As in the McDonald and Siegel (1986) model of an irreversible investment
opportunity, investment may be delayed indefinitely, thus the situation is equivalent to
6a perpetual call option over the underlying project.  The trigger point for the second
stage investment is denoted P2.
If it is found that P1 < P2, this may be interpreted as a situation in which a sleeping
patent is likely to arise.  Since discovery occurs randomly, commencement of research
at a price level below P2 does not guarantee the creation of a sleeping patent, since it
is possible for P to move above P2 before discovery actually takes place.  For a
sleeping patent to arise discovery itself must take place while the market price is below
P2; it is not sufficient that the firm merely engages in research over this range.
However, sleeping patents become a possibility whenever the firm carries out research
at a price level below P2.
Although the patent will not immediately be developed if innovation occurs while
the market price is in the range (P1, P2), this does not mean that exploitation is
unprofitable.  Rather the firm prefers to hold its option over the second stage due to
the irreversible nature of this investment combined with uncertainty in the product
market.  However, since the patent is potentially profitable, other firms would be
willing to develop it.  If a rival firm obtains a compulsory license on the grounds that
the patent-holder has failed to exploit the technology, it cannot then itself leave the
patent dormant, thus the licensee does not have the option to delay.  The ability for
other firms to gain access to the technology in this way effectively introduces
competition for development of the patent, restricting the ability of the inventor to
delay the second stage investment.
In section 6 the threat of compulsory licensing, or another similar measure, is
assumed to compel the firm to sink the second stage investment as soon as discovery
takes place.  Suspension at the intermediate stage is prevented and the compound
option problem is reduced to the simple choice of whether or not to engage in research
at any particular level of P.  This is something of a simplification.  In practice,
compulsory licensing will not take place unless there is another firm that wishes to
exploit the patent at this time.  However, as explained above, assuming that there are
other firms with the technical ability to use the patent, it is profitable for them to obtain
a license to do so.  Moreover, the payment of royalties to the patent-holder does not
overcome the problem.  If the license fee is less than the profit the patent-holder would
gain by exploiting the patent itself, then it will develop the technology rather than
allow it to be licensed.  If, on the other hand, the same level of profit can be extracted
7from the licensee by means of royalty payments, the situation is analytically equivalent
to the case in which the patent-holder itself exploits the patent without delay.  Thus, on
the assumption that there is a potential licensee who would wish to develop the patent,
the assumption is a reasonable one.
The decision rule for an optimizing firm in the two-stage model with suspension is
derived as follows.  Due to the compound option structure of the model, the
optimization problem must be solved backwards.  First, the value of the second stage
investment option and the level of the trigger point P2 must be found.  Once these
solutions have been obtained expressions for firm value during the first stage can be
derived.  A different set of optimality conditions is derived for each possible ordering
of the trigger points P1 and P2, which must both be solved in order to determine
optimal investment behavior.
3  The second stage: Irreversible capital investment
Viewed from the second stage alone, the firm’s decision problem is similar to the
McDonald and Siegel (1986) model of an irreversible investment project with a
constant investment cost, I.  The optimal investment time is found by solving the
following optimal stopping problem
( )  −−= ∫ ∞ −  max T trtT IdtwPeEV (2)
where E denotes the expectation, T is the unknown future stopping time at which the
investment is made, Pt is the market price at t, which evolves according to the
stochastic differential equation (1), and w and I are the flow and sunk costs
respectively.
Prior to investment at T the firm holds the opportunity to invest.  It receives no
expected cashflows but may experience a capital gain or loss on the value of its option.
Hence, in the continuation region (values of P for which it is not yet optimal to invest)
the Bellman equation for the value of the investment opportunity ( )PV0  is given by
8       ( )00 dVEdtrV = . (3)
Expanding 0dV  using Itô’s lemma we can write
( ) ( )( )2000 2
1 dPPVdPPVdV ′′+′= .
Substituting from (1), noting that µ = 0 and E(dz) = 0, we derive
( ) ( )dtPVPdVE 0220 2
1
′′= σ .
Hence the Bellman equation (3) becomes the following second-order differential
equation
( ) 0
2
1
00
22
=−′′ rVdtPVPσ . (4)
From (1) we can see that if P goes to zero it stays there forever.  Thus when P = 0
the option to invest has no value and ( )PV0  must satisfy the following boundary
condition
   ( ) 000 =V (5)
Solving the differential equation (4) subject to the boundary condition (5) we
obtain the following solution for the value of the option to invest in research
( ) 00 βBPPV = (6)
where B ≥ 0 is a constant whose value is yet to be determined,
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



++= 20
811
2
1
σ
β r  > 1 is the positive root of the characteristic equation
02 2
2
=−−
σ
εε
r
.
Next we consider the value of the firm in the stopping region (values of P for
which is it optimal to invest at once).  Since investment is irreversible, the value of the
firm in the stopping region ( )PV1  is given by the expected value of product market
profits, with no option value terms.  Thus, the expected value of investment when the
current market price is Pt is given by
( ) ( )  −= ∫∞ − ττ dwPeEPV t trt1 .
Since P has no expected trend (µ = 0) the expected value of immediate investment at t
is given by
       ( )
r
wP
PV tt
−
=1 . (7)
The boundary between the continuation region and the stopping region is given by
a critical value of the stochastic process, or “trigger point”, P2 such that continuation is
optimal for values of P below P2 and stopping (i.e. immediate investment) is optimal
above P2.  The optimal stopping time T is then the first time that the stochastic process
P hits the interval [P2, ∞).
Two conditions must hold at the optimal investment point.  First, the value of the
option held by the firm prior to investment, 0V , must equal the value of the completed
project, 1V , minus the sunk investment cost I (the “value-matching condition”)
    I
r
wP
BP −
−
=
2
2
0β
. (8)
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Optimality requires a second condition, known as “smooth-pasting,” to hold.  This
requires the value functions 0V  and 1V  to meet smoothly at P2 with equal first
derivatives7
       
r
BP 1120 0 =
−ββ . (9)
Using conditions (8) and (9), the following solutions for the second stage trigger
point P2 and constant of integration B can be derived
   ( )P w rI2 0
0 1
=
−
+
β
β ; (10)
and
     ( ) ( ) 10
1
0
0
0
1
−
−




+
−
= ββ
β β
rrIwB . (11)
4  The first stage: Research activity
To determine P1, the value of P at which the firm will commence and abandon
research, the value of the firm in the idle and active states must be analyzed as before.
In this case, however, the value function in the active state may take one of two forms,
depending upon whether or not P is sufficiently high that the second stage investment
would be sunk immediately if the discovery were to be made.  The three cases are
considered in turn, deriving the appropriate value function in each case.
4.1 The inactive firm
At low values of P no research activity is undertaken and the firm simply holds the
option to invest.  The derivation of the value of the firm follows that for ( )PV0  and is
given by
11
U P ZP0 0( ) = β (12)
where Z > 0 is an unknown constant and 0β  is as given above.
4.2 The active firm
If the firm undertakes research at a level of P for which it would choose to delay the
second stage investment (at any P < P2) the return to discovery is the value of the
option to invest.  Alternatively, if research is undertaken at a point where capital
investment would be undertaken immediately (at any P ≥ P2) the return to invention is
the expected NPV of the second stage investment project.  Thus, the value of the
active firm falls into the following two cases depending upon the current level of P.
(i) For P < P2
If the firm undertakes research at a level of P for which, if successful, it would not
wish to proceed with the irreversible capital investment at once (i.e. any P < P2), the
immediate payoff to discovery is the second stage option value V P BP0 0( ) = β .  The
value of a firm which carries out research over this range, derived in Appendix 1, is
given by
( )U P BP
ch
r h
XP YP1 0 1 1( ) = − + + +
−β α β (13)
where X and Y are unknown constants;
α
σ1 2
1
2
1 8 1= + + −




( )r h
 > 0; and
β
σ1 2
1
2
1 1 8= + + +




( )r h
 > 1.
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(ii) For P ≥ P2
If the firm carries out research at a level of P for which, if successful, it will undertake
the second stage investment and start production immediately (i.e. any P ≥ P2), the
return to discovery is the expected NPV, ( )PV1 .  The value of a firm which undertakes
research over this range, also derived in Appendix 1, is given by
( ) ( )( )U P
h
r r h
P w r I c WP2 1( ) = + − − − +
−α (14)
where W is an unknown positive constant.
4.3 The first stage optimization problem
Since there are two possible orderings of the trigger points P1 and P2, two separate
sets of optimality conditions must be constructed and solved.  The two cases, with the
relevant value functions in each range, are illustrated in figure 2.  When P1 ≥ P2 any
level of P at which the firm undertakes research is also one at which it would be willing
to proceed with the second stage investment immediately.  Thus, sleeping patents can
never arise in this case.  When P1 < P2, by contrast, the firm carries out research over
the range (P1, P2) and sleeping patents become a possibility, arising if the discovery
itself happens to occur within this range.
When the research technology is frictionless such that switching between research
activity and inactivity is costless, the value-matching and smooth-pasting conditions
will hold at any arbitrary switching point.  Thus, these conditions alone are not
sufficient to determine the optimal location of the trigger point P1.  To ensure that the
chosen switching point maximizes firm value an additional, first-order condition is
needed, while the second derivative must be negative.
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(i) For P1 ≥ P2
When P1 ≥ P2 the set of optimality conditions consists of three equations with three
unknowns (P1, W and Z).  At P1 the following value-matching and smooth-pasting
conditions must hold
( ) ( )U P U P0 1 2 1= ;
( ) ( )′ = ′U P U P0 1 2 1 .
The first-order condition determining the optimal location of P1 is given by
( ) ( )′ = ′ =U P Z P0 1 1 0 .
Solving this system the following expression for the first stage trigger point P1 is
obtained (details are given in Appendix 2); this expression for P1 is valid when the
resulting value is greater than or equal to P2
      ( )( ) ( )[ ]P w r I c1 1 01 01 1= + − + +
α β
α β . (15)
(ii) For P1 < P2
When P1 < P2 there are five equations with five unknowns (P1, W, X, Y and Z).  The
following value-matching and smooth-pasting conditions hold at P1
( ) ( )U P U P0 1 1 1= ;
( ) ( )′ = ′U P U P0 1 1 1 .
At P2, value-matching and smooth-pasting conditions are given respectively by
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( ) ( )U P U P1 2 2 2= ;
( ) ( )′ = ′U P U P1 2 2 2 .
As before, the first-order condition determining the optimal location of P1 is given by
( ) ( )′ = ′ =U P Z P0 1 1 0 .
The following expression for P1, which is valid when the resulting value is below P2,
can be derived (as in Appendix 2)
( )
( )( ) ( )P P
ch
w rI1 2
1 0 0
1 0 1 0
1
1 1
=
−
− + +




α β β
β β α β
β
 >  0. (16)
Although optimality conditions and solutions for the two cases can be derived, this
does not yet prove that it is possible for P2 to exceed P1 so that sleeping patents may
arise.  The next section derives conditions under which research is carried out
prospectively and demonstrates that, for sufficiently high uncertainty or a slow speed
of discovery, sleeping patents become a realistic possibility.
5 Prospective research and sleeping patents
In this section conditions are derived under which research is carried out prospectively
and sleeping patents may arise. For sleeping patents to be a possibility the first stage
trigger point P1 must lie strictly below the second stage trigger P2.  Then if discovery
occurs while the market price is in the range (P1, P2) the patent will be left dormant
until P2 is reached.  The ratio of first- and second-stage trigger points is denoted by ρ
as follows
ρ = P
P
1
2
. (17)
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Using this notation, sleeping patents are a possibility if and only if ρ falls below
unity.  When P1 ≥ P2, expression (15) for P1 can be used along with (10) for P2 to
derive an expression for ρ.  Thus we can derive
( )( )
( ) ( )ρ
α
α
=
+ +
+ +
w r I c
w rI
1
1 1
. (18)
Although this expression is valid only when P1 ≥ P2 it can be used to demonstrate
results over the full range of parameter values.  If it can be shown that ρ as defined by
expression (18) falls below unity at some point, then it must be true that the alternative
case holds at this level and P1 < P2.  Although the true value of ρ will no longer be
given by expression (18), it must nonetheless take some value less than unity.
The two propositions given below set out conditions under which research will be
undertaken prospectively and sleeping patents are likely to arise.
Proposition 1: For any set of parameter values {h, c, w, I, r}, there exists a critical
value of the volatility parameter, σ*, above which the first stage trigger point P1 lies
strictly below the second stage trigger point P2 and sleeping patents may arise.
Proof: The proof can be sketched as follows (full details are given in appendix 3).  The
existence of at least one critical value σ* at which ρ equals unity is demonstrated using
the intermediate value theorem.  Applying this theorem to the function ρ(σ), the
existence of some σ* ∈ (0, ∞) at which ρ = 1 can be demonstrated by showing that
(i) ρ(σ) tends towards some value greater than unity as σ approaches zero,
(ii) ρ(σ) tends to zero as σ approaches infinity, and
(iii) the function ρ(σ) is continuous.
The uniqueness of the critical value σ* is proven by demonstrating that ρ(σ) is strictly
monotonic; i.e. that ′ρ σ( )  is strictly negative for all values of σ in the range (0, ∞).
Thus, once the critical value σ* is exceeded, ρ is always less than unity (i.e. P1 < P2)
and sleeping patents are a possibility.
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Proposition 2:  For any set of parameter values {σ, w, I, r} and as long as the flow
research cost c is sufficiently small, there exists a critical value of the hazard rate, h*,
below which the first stage trigger point P1 falls below the second stage trigger point
P2 and sleeping patents may arise.
Proof: The structure of the proof is similar to that for proposition 1 above.  Details are
given in appendix 4.
An expression for the critical value σ* can be derived by setting ρ = 1 and
rearranging for σ to obtain
( )
( ) ( )( )σ* =
+
+ + +
rc
r h
w rI w r I c
2
. (19)
Similarly for h* we can derive
( ) ( )( )
( )h
w rI w r I c
rc
r* =
+ + +
−
σ 2
22
. (20)
Note, however, that the resulting value of h* must be positive, which will be the case
for sufficiently small c or large σ.
The results are illustrated using numerical simulations.  In the simulations described
below the following central parameter values are used.  The volatility parameter in the
geometric Brownian motion governing P is given by σ = 0.2.  The risk-free interest
rate is 0.05.  The parameters of the research technology are h = 0.5 and c = 4.  The
sunk and flow costs in the second stage are I = 10 and w = 0 respectively.  With these
parameter values the first stage trigger point is P1 = 1.08 while the second stage trigger
is P2 = 0.93.  Thus sleeping patents are impossible in this example: any value of P at
which the firm undertakes research is also one at which it would exploit the patent
immediately.
According to propositions 1 and 2 there are two cases in which research will be
carried out prospectively: firstly, if the degree of uncertainty is sufficiently high, or
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secondly, if both the hazard rate and flow research costs are sufficiently low.  These
cases, and the combination of the two parameters which together may result in
sleeping patents, are illustrated in the following three graphs.
Figure 3 shows the effect of increasing the volatility parameter, σ, while holding all
other parameter values constant.  Both P1 and P2 rise as volatility increases, but the
effect on P2 is more pronounced: although product market conditions clearly affect
research decisions, the ability to suspend the project after discovery reduces their
impact.  As described in proposition 1, a critical value is reached at which P1 crosses
P2; in this example σ* is approximately 0.355.
Figure 4 shows the effect of changing the hazard rate, h.  Unsurprisingly, there is
no effect on the second-stage trigger point P2.  However, the first-stage trigger point
P1 rises with h, causing research activity to be more delayed.  For values of h below a
critical level, h* = 0.125, P1 lies below P2 and sleeping patents are possible.
Figure 5 shows the locus of (σ, h) combinations at which the first and second stage
trigger points coincide (P1 = P2).  Below this locus, with a higher value of σ (greater
economic uncertainty) or lower value of h (a low expected rate of discovery), P2
exceeds P1 and sleeping patents are possible.
6 The constrained firm
We now consider the case of a firm that is constrained (under threat of compulsory
licensing or some other measure) to use its patent as soon as it is created.  The
compound option is reduced to a simple one in which the only decision taken by the
firm is the timing of its research activity; in this case the timing of the second stage
investment is given by the discovery date itself.  The trigger point at which the
constrained firm commences and abandons research is denoted PC.
When the firm is constrained to use the patent immediately its optimization
problem follows the analysis of section 4.3(i), with the solution denoted PC (rather
than P1 as above).  However, this result now holds over the complete range of P,
regardless of whether the resulting value is greater or less than P2.  If parameter values
are such that the (unconstrained) trigger point P1 exceeds P2, the constraint is non-
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binding and the “constrained” trigger point PC coincides with P1 (the two have
identical derivations).  In cases where P1 lies below P2, however, the constraint is
binding and PC will take some intermediate value between the two points.  Since PC is,
in effect, the trigger point for the second as well as the first stage investment, the firm
faces a trade-off between delaying research beyond the optimal trigger point P1 and
potentially having to sink the second stage investment before reaching the critical value
P2.
Figure 6 shows a numerical simulation comparing the constrained trigger point PC
with the unconstrained values P1 and P2.  Levels of P1, P2 and PC are shown for values
of the volatility parameter σ over the range (0.2, 0.7); other parameters take the values
given in section 5.  For values of σ below σ* = 0.35, the unconstrained first stage
trigger P1 exceeds P2 and the constraint is non-binding, thus PC coincides with P1.  For
values above σ*, however, the constraint binds and PC takes an intermediate value
between P1 and P2.  Thus in the constrained case research activity is further delayed,
until product market conditions are more favorable, compared with the behavior of the
unconstrained firm.
This finding has the following implications.  Policy measures to enforce the
development of sleeping patents, such as compulsory licensing, may cause one or both
of the following detriments.  By forcing the firm to exploit its patent immediately,
investment costs may be sunk too soon and society loses the value of the option to
delay.  When firms are forward-looking their research behavior is also affected.  As a
substitute for the option to hold a sleeping patent, the firm may instead choose to delay
its research activity relative to the social optimum.  Although new designs will be
brought to market more rapidly, they will be produced more slowly.
The constraint imposed on the firm’s option to delay is socially damaging in itself,
even in the absence of externalities.  However, if there are external benefits from
research, such as spillovers of knowledge to other firms, the delay in research activity
will be even more harmful.  In cases where the right to invest is auctioned, as is often
the case for oil leases, another consideration is the amount of revenue raised.  Any
constraint on the holder’s ability to hold options by delaying investment will reduce the
amount of revenue raised in auctioning these rights.
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7 Conclusions
This paper has studied the effects of technological uncertainty combined with risky
market conditions on the incentive for firms to engage in research.  In particular, it has
been shown that a sleeping patent may arise as the foreseeable outcome of socially
optimal behavior by the firm.  Thus, although the circumstances of individual cases
must be examined in detail before this conclusion can be drawn, observation of a
dormant but potentially profitable technology does not necessarily prove an anti-
competitive motive or otherwise socially harmful behavior.
When discovery occurs randomly, a firm that delays research until market
conditions are favorable cannot be certain that discovery will occur as soon as desired.
When market uncertainty is high or the expected speed of discovery is low, it may be
rational for the firm to engage in research at a time when the prevailing conditions
would not justify immediate market entry were the technology already available.  In
other words, the firm may find it worthwhile to incur initial expenditures to gain the
option to invest even at a time when this option would not itself be exercised.
In the context of the real options literature, this finding shows that the ability to
gain options for the future may make it rational to exercise current ones sooner.  Thus,
the existence of more options does not necessarily increase delay.  In such situations
the sequence of options available to the firm must be considered in its entirety, as
serious errors could be made if the early options were to be valued on their own.
The analysis has a number of implications for policy towards R&D.  First, by
demonstrating that sleeping patents may arise as the result of socially optimal
investment behavior under uncertainty, it suggests that they are not necessarily anti-
competitive or socially undesirable.  There are a number of reasons why a patent may
be left dormant and each case must be examined carefully before any such verdict is
made.  Secondly, the analysis suggests caution in adopting measures such as
compulsory licensing to enforce the exploitation of sleeping patents.  Forward-looking
firms will foresee the implications of such measures and may instead choose to delay
research activity itself, an outcome which could cause considerable social as well as
private detriment.
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Appendix 1:  The compound (first stage) option value
While the firm is idle, the derivation of the (option) value of the firm follows that for
the second stage value function ( )PV0 .  When the firm is active, however, there are
now two separate value functions to be derived, according to whether the current
value of P is below or above P2.
(i) For P < P2
If the firm undertakes research at a value of P for which, if successful, it would not
develop the patent at once (P < P2), the prize for discovery is the option value )(0 PV .
Incorporating this payoff, the dynamic programming equation is given by
( ) ( )( )U P hBP ch dt r h dt U P P U P dt1 1 2 2 10 1 12( ) ( ) ( )= − + − + + ′′ β σ  
which rearranges to give
          ( )r h U P hBP ch P U P+ = − + ′′1 2 2 10 12( ) ( )
β σ
 
. (A1.1)
Solving this differential equation, we obtain
U P hBP
r h
ch
r h
XP YP1
0
1 1( ) =
+ −
−
+
+ +−
β
α β
τ
(A1.2)
where X, Y are unknown constants;
α
σ1 2
1
2
1 8 1= + + −




( )r h
 > 0;
β
σ1 2
1
2
1 1 8= + + +




( )r h
 > 1; and
τ = ½ ( ) r=−1002 ββσ .
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The term τ is the expected growth rate of the second stage option ( )PV0 .
However, this simplifies to the interest rate r: since the option yields no cashflows, the
return on holding it is the capital growth alone which, in the absence of arbitrage
opportunities, must equal the risk-free interest rate r.  Thus, (A1.2) becomes
U P BP ch
r h
XP YP1 0 1 1( ) = − + + +
−β α β
. (A1.3)
Since this value function holds only over the range (P1, P2), there is no boundary
condition at zero or infinity that can be used to eliminate one of the constant terms.
(ii) For P ≥ P2
If the firm undertakes research at a level of P for which, if successful, it will sink the
capital investment and start production immediately (i.e. any P ≥ P2), the benefit from
discovery is the expected NPV of the second stage investment, ( )PV1 .  Incorporating
this payoff into the usual dynamic programming equation we obtain
( ) ( )( ) ( ) ( )U P h P w
r
I ch dt r h dt U P P U P dt2 2
2 2
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1
2
=
−
−
  −



 + − + + ′′
 σ  
which rearranges to give
( )r h U P h P w
r
I c P U P+ = − − −  + ′′2 2 2 2
1
2
( ) ( )σ
 
. (A1.4)
Solving this equation subject to the boundary condition ( )PU 2  → ( )PV1  as P → ∞
(i.e. the option value approaches the expected NPV of the project), the following
solution is obtained (where W is an unknown constant)
( ) ( )( )U P
h
r r h
P w r I c WP2 1( ) = + − − + +
−α
. (A1.5)
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Appendix 2:  Finding the first stage trigger point P1
Solutions must be found for two separate cases, P1 ≥ P2 and P1 < P2, which have
different optimality conditions.  Since an assumption concerning the relative sizes of P1
and P2 is made, the solution obtained in each case is valid only if the relevant
assumption is not violated by the outcome.
(i) For P1 ≥ P2
Value-matching, smooth-pasting and first order conditions at P1 are given by
( ) ( )( )ZP
h
r r h
P w r I c WP1 1 10 1
β α
=
+
− − + + − ; (A2.1)
( )β α
β α
0 1
1
1 1
10 1ZP h
r r h
WP− − −=
+
− ; (A2.2)
    ( )1PZ∂ / 1P∂  = 0. (A2.3)
Using (A2.1) and (A2.2) to eliminate W, we obtain
( ) ( ) ( ) ( ) ( )( )( )α β α α
β
1 0 1
1
1 1 1
0
1+ =
+
+ − + +
−
Z P
hP
r r h
P w r I c .
Differentiating with respect to P1 (the first order condition) we obtain
( ) ( )( ) ( )( )( )∂∂ α β β α
βZ
P
hP
r r h
w r I c P
1
1
1
1 0 0 1 1
0
1 1 0=
+
+ + − − + =
− −
.
Therefore
( )( ) ( )[ ]P w r I c1 1 01 01 1= + − + +
α β
α β . (A2.4)
The second derivative of Z(P) is negative, ensuring that P1 is a maximum.
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(ii) For P1 < P2
At P2, the value-matching and smooth-pasting conditions are given by
( )
( ) ( )
h P w rI
r r h
W X P BP YP2 2 2 21 0 1
− −
+
+ − = +−α β β ; (A2.5)
( ) ( )
h
r r h
W X P BP YP
+
− − = +− − − −α β βα β β1 2 1 0 2 1 1 2 11 0 1 . (A2.6)
Eliminating (W − X) and substituting the solutions for B and P2 we obtain
( ) ( )( )( )( )α β
α β
β
β
1 1 2
1 0
0
1
1
+ = −
+ +
− +
YP
w rI
r h
. (A2.7)
At P1, value-matching, smooth-pasting and first order conditions are given by
( )ZP BP
ch XP YP
r h1 1 1 1
0 0 1 1β β α β
= − + +
+
− ; (A2.8)
β β α ββ β α β0 1 1 0 1 1 1 1 1 1 1 10 0 1 1ZP BP XP YP− − − − −= − + ; (A2.9)
( )1PZ∂ / 1P∂  = 0. (A2.10)
Eliminating X and substituting for Y from (A2.7) we obtain
( ) ( )( )
( )
( )( )Z P B
P ch
r h
P P w rI
r h1
1 1
1 0
1 2
0
0 1 0 1
1
= −
+ +
−
+
− +
− − −β β β βα
α β β
Setting the first order condition ( )′Z P1  to zero, the following solution for P1 can be
derived (which is valid as long as the resulting value is strictly less than P2)
( )
( )( ) ( )P P
ch
w rI1 2
1 0 0
1 0 1 0
1
1 1
=
−
− + +




α β β
β β α β
β
. (A2.10)
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Appendix 3:  The possibility of sleeping patents when σ is large
The ratio of trigger points ρ(σ) is given by
 
( )( )
( )
( )
( )( )ρ
α σ
α σ
=
+ +
+ +
w r I c
w rI
1
1 1
. (A3.1)
To prove the existence and uniqueness of the critical point σ* at which ρ = 1, four
properties of the function ρ(σ) must be demonstrated.  First, that ρ(σ) approaches a
value greater than unity as σ → 0; second, that ρ(σ) → 0 as σ → ∞; third, that the
function is continuous; and fourth, that it is strictly monotonic for all values of σ in the
range (0, ∞).
(i) Limiting result as σ → 0
As σ → 0, ( )α σ1  → ∞ and α
α
1
1 1
1
+
→ .
Thus
    
( )( )
( )ρ →
+ +
+
w r I c
w rI
 > 1 as σ → 0. (A3.2)
Since c > 0, the limit of ρ(σ) as σ → 0 is a value greater than one.
(ii) Limiting result as σ → ∞
As σ → ∞, ( )α σ1  → 0 .
Thus
     ρ → 0 as σ → ∞. (A3.3)
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(iii) Continuity and monotonicity
In expression (A3.1) for ρ(σ), α1 is a continuous function of σ and all other elements
are independent of σ, thus ρ(σ) is continuous over the range (0, ∞).  In combination
with the limiting results presented in (i) and (ii), this proves the existence of at least
one critical value σ* at which ρ = 1.
To prove monotonicity of ρ(σ) and hence the uniqueness of σ*, the sign of the
(partial) derivative ( )′ρ σ  must be determined.
     
( )( )
( )
∂ρ
∂σ
∂
∂σ
α
α
=
+ +
+ +




w r I c
w rI
1
1 1
. (A3.4)
Thus,
sgn sgn∂ρ∂σ
∂
∂σ
α
α
=
+



11 1 = sgn
∂α
∂σ
1
.
( ) ( )∂α∂σ σ σ
1
3 2
1
22 2 1
8
= − + +
+









−
r h
r h   
  <  0. (A3.5)
The function ρ(σ) is strictly decreasing over the range (0, ∞).  Thus, the critical value
σ* at which ρ = 1 is unique.
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Appendix 4:  The possibility of sleeping patents when h is small
The ratio of trigger points ρ(h) is given by
( )( )
( )
( )
( )( )ρ
α
α
=
+ +
+ +
w r I c
w rI
h
h
1
1 1
. (A4.1)
(i) Limiting result as h → 0
When h = 0, α1 becomes
α α
σ1 0 2
1
2
1 8 1= = + −


r
 > 0.
Since α
α
1
1 1+
 < 1 and this ratio falls as σ rises, then, for sufficiently small c or large σ,
ρ will be less than unity.
(ii) Limiting result as h → ∞
As h → ∞, ( )α 1 h  → ∞ and ( )
α
α
1
1 1
1
+
→ .
Thus
     
( )( )
( )ρ →
+ +
+
w r I c
w rI
 > 1 as h → ∞. (A4.2)
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(iii) Continuity and monotonicity
In expression (A4.1), α1 is a continuous function of h while all other elements are
independent of h, thus ρ(h) is continuous over the range [0, ∞).  In combination with
the limiting results presented in parts (i) and (ii), the existence of at least one critical
value h* at which ρ(h) = 1 can be demonstrated using the intermediate value theorem.
To prove strict monotonicity and hence the uniqueness of h*, the sign of the
(partial) derivative ( )′ρ h  must be determined.
   
( )( )
( ) ( )
∂ρ
∂
∂
∂
α
αh
w r I c
w rI h
=
+ +
+ +




1
1 1
. (A4.3)
But
( )
∂
∂
α
αh
1
1 1+



 ( )= +
1
11
2
1
α
∂α
∂h .
Thus,
sgn ∂ρ∂h = sgn
∂α
∂
1
h
.
Taking the partial derivative of α1 with respect to h, we derive
( )∂α
∂ σ σ
1
2 2
1
22 1
8
h
r h
= +
+



−
  
 > 0. (A4.4)
The function ρ(h) is strictly increasing over the range (0, ∞).  Thus, the critical value
h* at which ρ = 1 is unique.
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Figure 1: The compound option model
Figure 2: Trigger points in the no sunk costs case
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     Figure 5: (σ, h) combinations giving rise to sleeping patents
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     Figure 6: Trigger points with and without ability to delay
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1
 This concept is illustrated by the 1955 Ealing comedy, “The Man in the White Suit,” in which the
creator of a dirt-repellent and (seemingly) indestructible fiber is offered £¼ million (then a
considerable fortune) by the owners of the clothing industry to suppress the invention.
2
 The 1977 Patents Act allows for compulsory licensing in three cases: (i) so that another patented
invention may be produced; (ii) so that the invention is “worked” (or the product manufactured) in
the UK or EC; and (iii) where the patentee refuses to exploit the new technology, yet it has market
potential and demand is not being met on reasonable terms.  For further details on UK and EC
patent law see Cornish (1996).
3
 Note that, if the patent is for a new product, this price may not be directly observable.  However, the
potential demand and market price may be inferred from customer surveys or the prices of existing
products.
4
 To be precise, the statement that a firm invests at a trigger point P* means that the firm invests at
the time when the stochastic process P first hits P*, approaching this level from below.
5
 Although the flow costs of research cannot be recovered, these should be thought of in the following
way.  In a period dt during which research is undertaken, the firm incurs a cost chdt in return for
which it receives a random return with an expected value given by hdt multiplied by the value of the
patent at that time.  Thus, the flow research cost is equivalent to production costs in a product
market model (although the return is stochastic in this case) and should not be recovered if the
project is later abandoned.
6
 Note that the number of research lines is not a choice variable for the firm.  Given that individual
lines are independent, the hazard rate of the entire project is given by h.1 = h.
7
 If smooth-pasting were violated and instead a kink arose at P2, a deviation from the supposedly
optimal policy would raise the firm’s expected payoff.  By delaying for a small interval of time after
the stochastic process first reached P2, the next step dP could be observed.  If the kink were convex,
the firm would obtain a higher expected payoff by entering if and only if P has moved (strictly)
above P2, since an average of points on either side of the kink give it a higher expected value than
the kink itself.  If the kink were concave, on the other hand, second order conditions would be
violated.  Continuation along the initial value function would yield a higher payoff than switching to
the alternative function and switching at P2 could not be optimal.  More detailed explanation of this
condition can be found in appendix C of chapter four in Dixit and Pindyck (1994).
